ライフサイエンスコーパス: bupropion

1 enhanced under paroxetine and reduced under bupropion.

2 imary rewards (erotic videos), but not under bupropion.

3 T and [(3)H]NE uptake inhibition relative to bupropion.

4 as alleviated by fluoxetine, reboxetine, and bupropion.

5 conditions, this decrement was attenuated by bupropion.

6 ibute to the smoking-cessation properties of bupropion.

7 ylamine > dextromethorphan > or = ketamine > bupropion.

8 y milk or by the dopamine reuptake inhibitor bupropion.

9 epin, dothiepin, fluoxetine, sertraline, and bupropion.

10 moking cessation medications varenicline and bupropion.

11 compared with placebo and 22% compared with bupropion.

12 A2A antagonist MSX-3 and the antidepressant bupropion.

13 mg/kg/injection, FR10 schedule) during 7-day bupropion (0.32-1.8 mg/kg/h) and risperidone (0.001-0.00

14 4), nicotine patch (1.68, 1.46 to 1.93), and bupropion (1.75, 1.52 to 2.01).

15 , 25% [511 of 2016 participants]), insomnia (bupropion, 12% [245 of 2006 participants]), abnormal dre

16 Treatment consisted of nine weeks of bupropion (150 mg a day for the first three days, and th

17 trial of varenicline (1 mg twice a day) and bupropion (150 mg twice a day) for 12 weeks with 12-week

18 participants [29.8%]; naltrexone 16 mg plus bupropion, 155 [27.2%]; placebo, 30 [5.3%]).

19 rcent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline,

20 treatment was nausea (naltrexone 32 mg plus bupropion, 171 participants [29.8%]; naltrexone 16 mg pl

21 ssation were associated with NRT (17.6%) and bupropion (19.1%) compared with placebo (10.6%).

22 A series of bupropion (1a) analogues (1b-1ff) were synthesized, and

23 For bupropion, 2.77 kg (CI, 1.1 to 4.5 kg) of weight was los

24 drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400

25 o-controlled comparison of sustained-release bupropion (244 subjects), a nicotine patch (244 subjects

26 ates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent

27 Bupropion (2a) analogues were synthesized and tested for

28 pants received open-label, sustained-release bupropion, 300 mg/d, for 7 weeks.

29 treatment were randomly assigned to receive bupropion, 300 mg/d, or placebo for 45 weeks and were su

30 trexone 32 mg per day plus sustained-release bupropion 360 mg per day combined in fixed-dose tablets

31 trexone 16 mg per day plus sustained-release bupropion 360 mg per day combined in fixed-dose tablets

32 placebo (n=4454) or naltrexone, 32 mg/d, and bupropion, 360 mg/d (n=4456).

33 kg (95% CrI, -6.06 to -4.52 kg); naltrexone-bupropion, 5.0 kg (95% CrI, -5.94 to -3.96 kg); lorcaser

34 for nicotine replacement treatment; 6557 for bupropion; 51,450 for varenicline) between Jan 1, 2007,

35 stat, 13 studies of fluoxetine, 5 studies of bupropion, 9 studies of topiramate, and 1 study each of

36 The results established that bupropion (a) inhibits epibatidine-induced Ca(2+) influx

37 oline receptor (nAChR) partial agonist, with bupropion, a norepinephrine/dopamine reuptake inhibitor,

38 The primary mechanism of action of bupropion, a smoking cessation drug, is commonly believe

39 (OR=1.76; 95% CI: 1.23-2.52) (p<0.005); for bupropion, abstinence was associated with CYP2B6 (OR=1.7

40 f nicotine patch, nicotine oral inhaler, and bupropion ad libitum (n = 63).

41 Treatment with sustained-release bupropion alone or in combination with a nicotine patch

42 re higher with combination therapy than with bupropion alone, but the difference was not statisticall

43 y significantly improve outcomes relative to bupropion alone.

44 inergic system although evidence exists that bupropion also has effects at nicotinic acetylcholine re

45 investigate the effect of sustained-release bupropion (amfebutamone) (SR) in promoting abstinence fr

46 in A(1), a proton pump inhibitor, but not by bupropion, an inhibitor of the plasma membrane DA transp

47 rate ratio was 1.09 (95% CI, 0.75-1.59) for bupropion and 2.59 (95% CI, 1.56-4.30) for topiramate.

48 rate ratio was 1.98 (95% CI, 1.02-3.84) for bupropion and 5.30 (95% CI, 2.54-11.04) for topiramate.

49 subjects), a nicotine patch (244 subjects), bupropion and a nicotine patch (245 subjects), and place

50 ompared with those whose mothers were in the bupropion and combination treatment groups).

51 The effects of bupropion and enantiomers of hydroxybupropion on human n

52 Racemic bupropion and hydroxybupropion inhibit [(3)H]norepinephr

53 crease DAT surface expression, we found that bupropion and ibogaine increased DAT surface expression,

54 Bupropion and ibogaine increased wild type DAT protein l

55 These data suggest that bupropion and ibogaine promote maturation of DAT by acti

56 type DAT, also blocked the rescue effects of bupropion and ibogaine.

57 e effect curves were generated for nicotine, bupropion and mecamylamine.

58 0 years was twice as high in patients taking bupropion and more than 5 times higher in patients takin

59 Those on bupropion and nicotine patch achieved higher abstinence

60 helping smokers achieve abstinence, whereas bupropion and nicotine patch were more effective than pl

61 edications used to treat tobacco dependence, bupropion and nicotine replacement therapy, are effectiv

62 nt differences between the sustained-release bupropion and placebo groups as measured by change in Ar

63 months (the end of the medication phase) for bupropion and placebo, respectively (P =.73).

64 Overall, these negative results with bupropion and risperidone are concordant with previous h

65 nt compounds: the monoamine uptake inhibitor bupropion and the dopamine antagonist risperidone.

66 icotine on response rates in the presence of bupropion and the nAChR antagonist, mecamylamine, as wel

67 <0.001), and 35.5 percent in the group given bupropion and the nicotine patch (P<0.001).

68 Both bupropion and topiramate are widely prescribed drugs.

69 6% had nicotine replacement therapy, 28% had bupropion, and 1% had varenicline.

70 While the nicotine lozenge, bupropion, and bupropion plus lozenge produced effects t

71 Lithium, quetiapine, olanzapine, bupropion, and carbamazepine were associated with high m

72 petitive inhibitors: mecamylamine, ketamine, bupropion, and dextromethorphan.

73 A or European Union are orlistat, naltrexone/bupropion, and liraglutide; in the USA, lorcaserin and p

74 Liraglutide, naltrexone/bupropion, and phentermine/topiramate are new agents tha

75 am, paroxetine, sertraline, venlafaxine, and bupropion, and their metabolites norfluoxetine and norse

76 vior changes associated with varenicline and bupropion, and these drugs' benefits outweigh potential

77 holamine uptake inhibitor and antidepressant bupropion, and this effect of bupropion was reversed by

78 fordability of nicotine replacement therapy, bupropion, and varenicline in the South Indian state of

79 ing cessation (nicotine replacement therapy, bupropion, and varenicline) are effective in patients wi

80 atments (nicotine replacement therapy [NRT], bupropion, and varenicline), which is most effective in

81 tion therapies-nicotine replacement therapy, bupropion, and varenicline-were associated with an incre

82 Both bupropion- and potassium-stimulated dopamine release wer

83 eation treated with paroxetine compared with bupropion appeared to experience greater acute improveme

84 Both nortriptyline and bupropion are efficacious in producing abstinence in cig

85 gest that clinical and behavioral effects of bupropion arise from actions at nAChR as well as DA and

86 re potent than the (2S,3R) isomer or racemic bupropion as an antagonist of alpha(4)beta(2) (functiona

87 Our meta-analysis suggests varenicline and bupropion, as well as individual and telephone counselin

88 were randomly assigned to receive placebo or bupropion at a dose of 100, 150, or 300 mg per day for s

89 55 mg per day) to receive sustained-release bupropion (at a dose of up to 400 mg per day) as augment

90 up, n = 511); augment current treatment with bupropion (augment-bupropion group, n = 506); or augment

91 e 16% with nicotine patch alone and 28% with bupropion augmentation (odds ratio=2.04, 95% CI=1.03-4.0

92 (control condition); "rescue" treatment with bupropion augmentation of the patch; or rescue treatment

93 o precessation nicotine patch benefited from bupropion augmentation; abstinence rates at end of treat

94 er drug candidate for smoking cessation than bupropion because of its higher potency at the relevant

95 ly higher quit rates in intervention groups (bupropion/behavioural support versus placebo in Pakistan

96 was observed among individuals treated with bupropion (beta [SE]: -0.063 [0.027]; P = .02), amitript

97 t was established that both mecamylamine and bupropion block nicotine's rate-reducing effects.

98 gesting either a placebo (pla) or 2 x 300 mg bupropion (bup), prior to exercise in temperate (18 degr

99 , including nicotine replacement therapy and bupropion, can increase cessation rates.

100 Neither behavior-based nor bupropion cessation interventions improved cessation rat

101 ment of unipolar major depression in adults: bupropion, citalopram, duloxetine, escitalopram, fluoxet

102 tte smokers, combined use of varenicline and bupropion, compared with varenicline alone, increased pr

103 ained-release combination of naltrexone plus bupropion could be a useful therapeutic option for treat

104 Bupropion did not initiate abstinence among smokers who

105 Bupropion did not reduce relapse to smoking in smokers w

106 Augmentation with sustained-release bupropion does have certain advantages, including a grea

107 Bupropion doubles quit rates in otherwise healthy smoker

108 en administered in the presence of nicotine, bupropion elicits unique pharmacological differences suc

109 It appears that bupropion enabled subjects to maintain a greater TT powe

110 r pargyline, and the atypical antidepressant bupropion, even though they did not differ in baseline i

111 tte smokers; however, the mechanism by which bupropion exerts this effect has not yet been described.

112 lication, our findings suggest that prenatal bupropion exposure may be associated with reductions in

113 Collectively, our data indicate that bupropion first binds to the resting AChR, decreasing th

114 ks of bupropion treatment, sustained-release bupropion for 12 months delayed smoking relapse and resu

115 ychotherapy and adjunctive sustained-release bupropion for nicotine addiction in patients with schizo

116 tment with varenicline and sustained-release bupropion for smokers who, based on an assessment of ini

117 trolled trial of a sustained-release form of bupropion for smoking cessation.

118 hese findings suggest that combining CM with bupropion for the treatment of cocaine addiction may sig

119 uture studies should compare higher doses of bupropion for treating sexual dysfunction and should inc

120 icotine-patch group (6.6 percent), 29 in the bupropion group (11.9 percent), and 28 in the combined-t

121 RR, 1.19 [95% CI, 1.09-1.29]) or the augment-bupropion group (65.6%; RR, 1.13 [95% CI, 1.04-1.23]).

122 oup and 90 patients (2.0%) in the naltrexone-bupropion group (HR, 0.88; adjusted 99.7% CI, 0.57-1.34)

123 95% CI, 1.91-4.19; P<.001) and 20.2% in the bupropion group (OR, 1.69; 95% CI, 1.19-2.42; P = .003).

124 up, -6.1% (0.3) in the naltrexone 32 mg plus bupropion group (p<0.0001 vs placebo) and -5.0% (0.3) in

125 and -5.0% (0.3) in the naltrexone 16 mg plus bupropion group (p<0.0001 vs placebo).

126 he nicotine-patch group, 30.3 percent in the bupropion group (P<0.001), and 35.5 percent in the group

127 prazole group [n = 84]; and 22.5% in augment-bupropion group [n = 114]).

128 revalence abstinence rates were 37.2% in the bupropion group and 32.0% in the placebo group (p = 0.33

129 The sustained-release bupropion group and the buspirone group had similar rate

130 in the combined-treatment group than in the bupropion group and the placebo group (P<0.05 for both c

131 continuous abstinence rate was higher in the bupropion group than in the placebo group at study week

132 Weight gain was significantly less in the bupropion group than in the placebo group at study weeks

133 g abstinence was significantly higher in the bupropion group than in the placebo group at the end (we

134 e varenicline group, 22 (2.2%) of 989 in the bupropion group, 25 (2.5%) of 1006 in the nicotine patch

135 varenicline group, 68 (6.7%) of 1017 in the bupropion group, 53 (5.2%) of 1016 in the nicotine patch

136 switch group, 26.9% (n = 136)for the augment-bupropion group, and 28.9% (n = 146) for the augment-ari

137 icotine-patch group, a gain of 1.7 kg in the bupropion group, and a gain of 1.1 kg in the combined-tr

138 e effects were more common in the naltrexone-bupropion group, including gastrointestinal events in 14

139 nt current treatment with bupropion (augment-bupropion group, n = 506); or augment with an atypical a

140 Anxiety was more frequent in the 2 bupropion groups (24.3% in the switch group [n = 124] vs

141 re also more frequent in the naltrexone plus bupropion groups than in the placebo group.

142 mm Hg below baseline in the naltrexone plus bupropion groups.

143 acement therapy (NRT) and the antidepressant bupropion have been shown to significantly increase cess

144 obacco other than cigarettes; current use of bupropion; having a current psychosis or schizophrenia d

145 nt with either cognitive-behavioral therapy, bupropion HCl, or pill placebo.

146 replacement therapies and the antidepressant bupropion helps people stop smoking.

147 Sustained-release bupropion, however, was associated with a greater reduct

148 Sustained-release bupropion hydrochloride and nortriptyline hydrochloride

149 iven the actions of varenicline tartrate and bupropion hydrochloride sustained-release (SR) on neurob

150 Bupropion hydrochloride treatment reduces cue-induced cr

151 Sustained-release bupropion hydrochloride was started at 150 mg/d and incr

152 Participants receiving bupropion hydrochloride were given 300 mg/d beginning at

153 pharmacotherapy (paroxetine hydrochloride or bupropion hydrochloride) (n = 88), CBT (n = 90), or comm

154 ined the risk of angle-closure glaucoma with bupropion hydrochloride, a unique, popular antidepressan

155 (eg, nefazodone hydrochloride, mirtazapine, bupropion hydrochloride, and venlafaxine hydrochloride)

156 ption including amitriptyline hydrochloride, bupropion hydrochloride, citalopram hydrobromide, duloxe

157 e non-selective serotonin reuptake inhibitor bupropion hydrochloride, even though it carries the same

158 nicotine nasal spray, nicotine inhaler, and bupropion hydrochloride.

159 note response, 76% of the subjects receiving bupropion improved, compared to 37% of the subjects rece

160 ation to determine the anti-ADHD efficacy of bupropion in adult patients with DSM-IV ADHD.

161 Use of bupropion in combination with nicotine replacement thera

162 Use of sustained-release bupropion in combination with supportive group therapy m

163 effective than placebo, nicotine patch, and bupropion in helping smokers achieve abstinence, whereas

164 ally and statistically significant effect of bupropion in improving ADHD in adults.

165 though 2 previous trials examined the use of bupropion in patients hospitalized with acute cardiovasc

166 The results suggest a therapeutic role for bupropion in the armamentarium of agents for ADHD in adu

167 of varenicline relative to both placebo and bupropion, indicating considerable benefit without evide

168 Bupropion interacts with a luminal binding domain shared

169 Bupropion is an atypical antidepressant that also has us

170 Treatment with bupropion is associated with improved ability to resist

171 avioral support alone or in combination with bupropion is effective in promoting cessation in smokers

172 However, bupropion is not effective for smoking cessation in pati

173 Bupropion is well tolerated and seems to be safe to use

174 ause hydroxybupropion, a major metabolite of bupropion, is believed to contribute to its antidepressa

175 itivity to amphetamine (Kd: 0.75 microM) and bupropion (Kd: 1.5 microM).

176 ng safety, serotonin reuptake inhibitors and bupropion may have lower rates of manic switch than tric

177 Combining patch with gum or patch with bupropion may increase the quit rate compared with any s

178 fic genes, and genes involved in nicotine or bupropion metabolism).

179 onergic-specific (non-SSRI) antidepressants (bupropion, mirtazapine, nefazodone, and venlafaxine), tr

180 eeks of treatment compared with switching to bupropion monotherapy.

181 patch (n=623), nicotine nasal spray (n=189), bupropion (n=213), or placebo (n=192).

182 signed either to switch to sustained-release bupropion (N=239), sertraline (N=238), or extended-relea

183 receive augmentation with sustained-release bupropion (N=279) or buspirone (N=286).

184 clinical pilot trial of paroxetine (N=36) or bupropion (N=38) in DSM IV major depression with a suici

185 (N=86; sertraline [N=27], sustained-release bupropion [N=28], or extended-release venlafaxine [N=31]

186 medication (N=117; either sustained-release bupropion [N=56] or buspirone [N=61]) or switch to cogni

187 plus bupropion, n=583; naltrexone 16 mg plus bupropion, n=578; placebo, n=581).

188 ouble-blind treatment (naltrexone 32 mg plus bupropion, n=583; naltrexone 16 mg plus bupropion, n=578

189 e lozenge, nicotine patch, sustained-release bupropion, nicotine patch plus nicotine lozenge, bupropi

190 Neither bupropion nor varenicline showed an increased risk of an

191 ouped by whether they required augmentation (bupropion, nortriptyline, or lithium) and compared on li

192 ng sites and the mechanisms of inhibition of bupropion on muscle-type nicotinic acetylcholine recepto

193 to receive 8 weeks of treatment with either bupropion or a matching placebo pill (double-blind).

194 epressant or augmentation of citalopram with bupropion or buspirone (second step), adult outpatients

195 of citalopram with either sustained-release bupropion or buspirone appears to be useful in actual cl

196 ne or an augmentation with sustained-release bupropion or buspirone was provided (level 2).

197 her, the effect of in vivo administration of bupropion or mecamylamine on nicotine-stimulated (86)Rb(

198 ceive either 150 mg/day of sustained-release bupropion or placebo at 6:00 p.m. for 3 weeks.

199 participants were eligible to be assigned to bupropion or placebo for 6 months (for relapse preventio

200 participants were eligible to be assigned to bupropion or placebo for 8 weeks of treatment.

201 Participants received bupropion or placebo for 9 weeks and were followed for 1

202 therapy, 3.1% and 0.0% stopped smoking with bupropion or placebo, respectively (P =.12).

203 gned to receive 12 weeks of varenicline plus bupropion or varenicline plus placebo.

204 OR, 2.95; 95% CrI, 2.11-4.23) and naltrexone-bupropion (OR, 2.64; 95% CrI, 2.10-3.35) were associated

205 16-7.78; SUCRA, 0.83), 55% taking naltrexone-bupropion (OR, 3.96; 95% CrI, 3.03-5.11; SUCRA, 0.60), 4

206 er a switch to sertraline, sustained-release bupropion, or extended-release venlafaxine or an augment

207 double-blind 12-week trial of escitalopram, bupropion, or the combination of the two in depressed mo

208 who use nicotine replacement therapy (NRT), bupropion, or varenicline when trying to quit double the

209 eplacement treatment (NRT; reference group), bupropion, or varenicline.

210 226 (48%) assigned to naltrexone 32 mg plus bupropion (p<0.0001 vs placebo) and 186 (39%) assigned t

211 186 (39%) assigned to naltrexone 16 mg plus bupropion (p<0.0001 vs placebo).

212 ese adults, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide, comp

213 ce in the heat was significantly improved by bupropion (pla: 39.8 +/- 3.9 min, bup: 36.4 +/- 5.7 min;

214 stigate their role in smoking cessation in a bupropion placebo-controlled randomized clinical trial.

215 The varenicline-placebo and bupropion-placebo RDs were 1.59 (95% CI -0.42 to 3.59) a

216 The varenicline-placebo and bupropion-placebo risk differences (RDs) for moderate an

217 While the nicotine lozenge, bupropion, and bupropion plus lozenge produced effects that were compar

218 opion, nicotine patch plus nicotine lozenge, bupropion plus nicotine lozenge, or placebo.

219 The dopamine reuptake inhibitor bupropion potently inhibited fictive swimming, demonstra

220 istat, phentermine, probably diethylpropion, bupropion, probably fluoxetine, and topiramate promote m

221 , combination treatment with varenicline and bupropion proved more efficacious than varenicline alone

222 Lithium, venlafaxine, bupropion, quetiapine, olanzapine, ziprasidone, valproic

223 than in the acute and continuation trials of bupropion (ratios=0.85 and 1.17, respectively) and sertr

224 ing 21 nicotine replacement therapy RCTs, 28 bupropion RCTs, and 18 varenicline RCTs, we found no inc

225 ime to relapse was significantly greater for bupropion recipients than for placebo recipients (156 da

226 dverse events attributable to varenicline or bupropion relative to nicotine patch or placebo.

227 sk of all cardiovascular disease events with bupropion (relative risk [RR], 0.98; 95% confidence inte

228 scale scores, 52% of the subjects receiving bupropion reported being "much improved" to "very improv

229 Lamotrigine and bupropion represent new treatments for neuropathic pain.

230 rent loci are associated with varenicline vs bupropion response, suggesting that additional research

231 ar events, we found a protective effect with bupropion (RR, 0.45; 95% CI, 0.21-0.85) and no clear evi

232 ement therapy (RR, 1.60 [CI, 1.53 to 1.68]), bupropion (RR, 1.62 [CI, 1.49 to 1.76]), and varenicline

233 95% confidence interval [CI], 1.34-5.21) and bupropion (RR: 1.42; 95% CI, 1.01-2.01) were associated

234 in regions from rats administered 30.0 mg/kg bupropion (s.c.) 15 min prior to dissection compared to

235 tion and/or antidepressants and to elucidate bupropion's possible mechanisms of action(s), 23 analogu

236 The bupropion-selective genes were nominated by bupropion-se

237 bupropion-selective genes were nominated by bupropion-selective results.

238 of 228 acute (10-week) randomized trials of bupropion, sertraline, or venlafaxine as an adjunct to a

239 This result suggests that bupropion shares behavioral effects with mecamylamine wh

240 15 or more cigarettes per day, were assigned bupropion SR (150 mg twice daily) or placebo for 12 week

241 were randomly assigned to receive 150 mg of bupropion SR (n = 300) or placebo (n = 300) twice daily

242 95% CI, 1.95-4.91; P<.001) and vs 16.1% for bupropion SR (OR, 1.46; 95% CI, 0.99-2.17; P = .057).

243 al [CI], 2.70-5.50; P<.001) and vs 29.5% for bupropion SR (OR, 1.93; 95% CI, 1.40-2.68; P<.001).

244 enicline [28.1%]) and insomnia (72 receiving bupropion SR [21.9%]).

245 ling for continuous abstinence, those taking bupropion SR also gained less weight than those taking p

246 Secondary analyses suggest that bupropion SR and cognitive behavioral therapy may be eff

247 ints and significantly more efficacious than bupropion SR at the end of 12 weeks of drug treatment an

248 Those taking bupropion SR experienced a greater mean reduction in dep

249 95% CI, 1.72-4.11; P<.001) and 14.6% in the bupropion SR group (OR, 1.77; 95% CI, 1.19-2.63; P = .00

250 al [CI], 2.69-5.50; P<.001) and 29.8% in the bupropion SR group (OR, 1.90; 95% CI, 1.38-2.62; P<.001)

251 nd of 7 weeks of treatment were 36.0% in the bupropion SR group and 19.0% in the placebo group (17.0

252 pants in the varenicline group, 12.6% in the bupropion SR group, and 7.3% in the placebo group.

253 Twelve weeks of varenicline and bupropion SR or varenicline and placebo.

254 gnificantly higher in participants receiving bupropion SR than in those receiving placebo (28% [57/20

255 ) were also higher in participants receiving bupropion SR than in those taking placebo (p<0.05).

256 ne titrated to 1 mg twice daily (n = 344) or bupropion SR titrated to 150 mg twice daily (n = 342) or

257 ne titrated to 1 mg twice per day (n = 352), bupropion SR titrated to 150 mg twice per day (n = 329),

258 Bupropion SR was also significantly more efficacious tha

259 Bupropion SR was effective for smoking cessation among A

260 Twelve weeks of varenicline, bupropion SR, or placebo plus intensive smoking cessatio

261 m efficacy exceeded that of both placebo and bupropion SR.

262 ithdrawal were attenuated in those receiving bupropion SR.

263 Bupropion SRis a well-tolerated and effective aid to smo

264 among smokers with AMI to determine whether bupropion, started in-hospital, is safe and can improve

265 Switch to a different antidepressant, bupropion (switch group, n = 511); augment current treat

266 support sessions (BSS), BSS plus 7 weeks of bupropion therapy (BSS+), or usual care.

267 Adjusted rate ratios were computed for bupropion, topiramate (positive control group drug), and

268 Three other drugs, bupropion, topiramate, and ciliary neurotrophic factor,

269 zine, imipramine, amitriptyline, duloxetine, bupropion, trazodone, tianeptine, and agomelatine.

270 ence of at least one minor (C) allele in the bupropion-treated group (OR=0.43; 95% CI=0.22-0.77; P=0.

271 Bupropion-treated participants reported less craving and

272 bo-treated patients (1.3%) and 35 naltrexone-bupropion-treated patients (0.8%; HR, 0.59; 95% CI, 0.39

273 nt increased methamphetamine choice, whereas bupropion treatment did not alter methamphetamine choice

274 Bupropion treatment was associated with a significant ch

275 At the end of open-label bupropion treatment, 461 of 784 participants (58.8%) wer

276 the 95% CI of the HR for MACE for naltrexone-bupropion treatment, compared with placebo, did not exce

277 persons who stopped smoking with 7 weeks of bupropion treatment, sustained-release bupropion for 12

278 eats min(-1); P = 0.039), were higher in the bupropion trial than in the placebo.

279 In the bupropion trial, smokers carrying the C allele also repo

280 mparing patients receiving sustained-release bupropion (up to 200 mg b.i.d.) (N=21) to patients recei

281 Findings about the harms related to bupropion use were mixed.

282 nagement vs psychological intervention) x 3 (bupropion vs nortriptyline vs placebo) randomized trial.

283 ctive influences on therapeutic responses to bupropion vs NRT.

284 Chronic and acute use of bupropion was associated with reduced UBF, even after co

285 atment with sustained-release naltrexone and bupropion was developed to produce complementary actions

286 A sustained-release form of bupropion was effective for smoking cessation and was ac

287 antidepressant bupropion, and this effect of bupropion was reversed by either D1 or D2 family antagon

288 stigation of the efficacy of varenicline and bupropion, we examined whether genes important in the ph

289 In addition, (2S,3S)-hyroxybupropion and bupropion were considerably more potent than (2R, -3R)-h

290 to cocaine, the DAT blockers nomifensine and bupropion were less effective at inhibiting dopamine upt

291 revalence abstinence, both nortriptyline and bupropion were more efficacious than placebo.

292 safety risk and efficacy of varenicline and bupropion with nicotine patch and placebo in smokers wit

293 authors compared low-dose sustained-release bupropion with placebo for sexual dysfunction induced by

294 highest relative risk of such switching and bupropion with the lowest risk.